Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LNTH NASDAQ:PCVX NASDAQ:PTCT NASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNTHLantheus$54.90-1.1%$69.20$47.25▼$118.21$3.77B0.142.62 million shs1.03 million shsPCVXVaxcyte$30.79+0.1%$33.34$27.66▼$121.06$3.99B1.211.52 million shs944,896 shsPTCTPTC Therapeutics$49.33-0.9%$48.74$30.41▼$58.38$3.96B0.541.26 million shs906,924 shsSYRESpyre Therapeutics$16.49-1.4%$16.29$10.91▼$40.26$1.01B2.82466,120 shs351,933 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNTHLantheus-1.08%-5.69%-23.58%-27.29%-49.96%PCVXVaxcyte+0.06%-4.65%-11.57%-5.55%-60.74%PTCTPTC Therapeutics-0.92%-2.45%-3.16%+1.04%+40.18%SYRESpyre Therapeutics-1.38%-5.12%-4.63%+8.13%-41.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLNTHLantheus4.771 of 5 stars4.41.00.04.23.22.51.9PCVXVaxcyte2.4012 of 5 stars3.52.00.00.03.51.70.0PTCTPTC Therapeutics4.2609 of 5 stars4.31.00.04.41.70.81.3SYRESpyre Therapeutics3.0855 of 5 stars3.62.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLNTHLantheus 2.71Moderate Buy$105.5092.17% UpsidePCVXVaxcyte 3.09Buy$136.50343.33% UpsidePTCTPTC Therapeutics 2.63Moderate Buy$69.1540.19% UpsideSYRESpyre Therapeutics 3.29Buy$53.40223.83% UpsideCurrent Analyst Ratings BreakdownLatest SYRE, PCVX, PTCT, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$79.00 ➝ $73.008/20/2025PTCTPTC TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$76.00 ➝ $71.008/20/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$82.00 ➝ $76.008/11/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Hold$111.00 ➝ $63.008/8/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$70.008/8/2025PTCTPTC TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold8/8/2025PTCTPTC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$60.00 ➝ $63.008/8/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$78.00 ➝ $79.008/7/2025PCVXVaxcyteCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/7/2025LNTHLantheusJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$112.00 ➝ $73.008/7/2025LNTHLantheusMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$120.00 ➝ $70.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLNTHLantheus$1.53B2.43$7.02 per share7.82$17.16 per share3.20PCVXVaxcyteN/AN/AN/AN/A$23.66 per shareN/APTCTPTC Therapeutics$806.78M4.86N/AN/A($2.60) per share-18.97SYRESpyre Therapeutics$890K1,119.10N/AN/A$4.97 per share3.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLNTHLantheus$312.44M$3.7614.608.70N/A17.82%34.06%19.10%11/5/2025 (Estimated)PCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.977.08N/AN/A35.65%-106.31%30.61%11/6/2025 (Estimated)SYRESpyre Therapeutics-$208.02M-$3.40N/AN/AN/AN/A-71.30%-38.69%11/6/2025 (Estimated)Latest SYRE, PCVX, PTCT, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025PTCTPTC Therapeutics-$1.07-$0.83+$0.24-$0.83$173.01 million$178.88 million8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 million8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A8/5/2025Q2 2025SYRESpyre Therapeutics-$0.73-$0.49+$0.24-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLNTHLantheusN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLNTHLantheus0.494.294.07PCVXVaxcyteN/A11.1111.11PTCTPTC TherapeuticsN/A3.623.57SYRESpyre TherapeuticsN/A6.496.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLNTHLantheus99.06%PCVXVaxcyte96.78%PTCTPTC TherapeuticsN/ASYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipLNTHLantheus1.50%PCVXVaxcyte3.10%PTCTPTC Therapeutics5.50%SYRESpyre Therapeutics15.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLNTHLantheus70067.99 million66.97 millionOptionablePCVXVaxcyte160129.82 million125.80 millionOptionablePTCTPTC Therapeutics1,41079.44 million75.07 millionOptionableSYRESpyre Therapeutics7360.40 million51.08 millionOptionableSYRE, PCVX, PTCT, and LNTH HeadlinesRecent News About These CompaniesAffinity Asset Advisors LLC Decreases Holdings in Spyre Therapeutics, Inc. $SYREAugust 28 at 9:02 AM | marketbeat.comVanguard Group Inc. Buys 51,794 Shares of Spyre Therapeutics, Inc. $SYREAugust 28 at 3:12 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Upgraded by Wall Street Zen to "Hold" RatingAugust 25, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Up 8.5% - Here's WhyAugust 15, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 12, 2025 | marketbeat.comXTX Topco Ltd Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE)August 9, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from WedbushAugust 7, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPSAugust 6, 2025 | marketbeat.comSpyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 5, 2025 | globenewswire.comTD Asset Management Inc Has $361,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)August 5, 2025 | marketbeat.comJefferies Financial Group Inc. Acquires 31,900 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)August 2, 2025 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsAugust 1, 2025 | globenewswire.comSpyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comHere's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn SituationJuly 16, 2025 | finance.yahoo.comSYRE - Spyre Therapeutics Inc Trailing Returns - MorningstarJuly 4, 2025 | morningstar.comMSpyre Therapeutics Announces Grants of Inducement AwardsJuly 3, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)June 20, 2025 | theglobeandmail.comSpyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways ForwardJune 18, 2025 | seekingalpha.comSpyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development ...June 17, 2025 | finanznachrichten.deSpyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 ReadoutsJune 17, 2025 | prnewswire.comSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025June 16, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSYRE, PCVX, PTCT, and LNTH Company DescriptionsLantheus NASDAQ:LNTH$54.90 -0.60 (-1.08%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$55.54 +0.65 (+1.17%) As of 08/29/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Vaxcyte NASDAQ:PCVX$30.79 +0.02 (+0.06%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$30.78 0.00 (-0.02%) As of 08/29/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.PTC Therapeutics NASDAQ:PTCT$49.33 -0.46 (-0.92%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$49.32 -0.01 (-0.02%) As of 08/29/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Spyre Therapeutics NASDAQ:SYRE$16.49 -0.23 (-1.38%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$16.48 0.00 (-0.03%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
